Biotech
-
Permission granted by Cerevel Therapeutics
Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s study
Analysts had low expectations for Cerevel’s drug tavapadon, which was something of an afterthought in AbbVie’s proposed buyout of the biotech.
By Ned Pagliarulo • April 18, 2024 -
Douglas Cliff via Getty Images
Emerging biotechMetsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo
It’s “early innings” in the obesity drug race, said Metsera CEO Clive Meanwell, whose company acquired a portfolio of medicines it aims to test in combination.
By Ben Fidler • April 18, 2024 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches.
By BioPharma Dive staff -
noparrit via Getty Images
Sage’s cognition drug fails in Parkinson’s study
Following negative results, the company doesn’t plan to further test SAGE-718 in Parkinson’s. Other studies in Huntington’s and Alzheimer’s remain ongoing.
By Jacob Bell • April 17, 2024 -
Permission granted by Canaan
Canaan hires Pfizer executive, reels in $100M for biotech investing
The firm has brought in as venture partner Uwe Schoenbeck, who most recently was the top scientist for Pfizer’s emerging science and innovation unit.
By Gwendolyn Wu • April 17, 2024 -
Dr_Microbe via Getty Images
Cullinan changes name, pivots to autoimmune disease
The biotech says a dual-pronged antibody it’s developing could become an “off-the-shelf” alternative to cell therapies in development for lupus and other inflammatory conditions.
By Kristin Jensen • April 16, 2024 -
Courtesy of Alexandria Real Estate Equities
Q&A // Emerging biotechBiotech landlord Alexandria on research clusters and the sector’s recovery
Joel Marcus, the longtime head of Alexandria Real Estate Equities, sees few near-term challengers to the established biotech hubs of Boston, San Diego and San Francisco.
By Gwendolyn Wu • April 16, 2024 -
Permission granted by Neumora Therapeutics
Neumora’s schizophrenia drug hit with clinical hold
Shares of the biotech dipped by double digits following disclosure the FDA had paused an early-stage study of Neumora’s muscarinic-targeting drug.
By Jacob Bell • April 15, 2024 -
Regeneron commits $500M to new venture capital fund
While corporate venture arms are commonplace among pharmaceutical companies, the new fund announced Monday is Regeneron’s first.
By Delilah Alvarado • April 15, 2024 -
Spencer Platt via Getty Images
Biotech IPOs bounced back in first quarter, but backlog remains
Proceeds from biotech IPOs during the first three months of 2024 matched levels seen in the first quarters of 2019 and 2020, BioPharma Dive data show.
By Gwendolyn Wu • April 12, 2024 -
luismmolina via Getty Images
Emerging biotechCentury buys a startup, raises funding in cell therapy expansion
The biotech is acquiring Clade Therapeutics and its stem cell technology at a discount price, while adding $60 million via a private placement led by Bain Capital.
By Delilah Alvarado • April 11, 2024 -
PeopleImages via Getty Images
J&J, Rallybio partner on drug development for rare fetal condition
The biotech is working on a preventive therapy for the immune disorder, known as FNAIT for short, while J&J is studying its drug nipocalimab as a treatment.
By Delilah Alvarado • April 10, 2024 -
whitehoune via Getty Images
Emerging biotechPureTech launches Seaport, hoping to create Karuna 2.0
The startup is taking aim at anxiety with $100 million from high-profile biotech backers like ARCH, Sofinnova and Third Rock.
By Jacob Bell • April 9, 2024 -
Adene Sanchez via Getty Images
Private biotech funding rises as venture firms deploy cash
Twenty-six drugmakers closed fundraising rounds worth more than $100 million in the first quarter, according to HSBC data shared with BioPharma Dive.
By Gwendolyn Wu • April 8, 2024 -
Permission granted by Bristol Myers Squibb
Deep DivePsychiatry drugs finally have pharma’s attention. Can they keep it?
Recent biotech company acquisitions have put emerging schizophrenia treatments in focus. But many development hurdles still stand in the way of new medicines for the brain.
By Jacob Bell • April 8, 2024 -
Michael M. Santiago via Getty Images
Emerging biotechContineum prices biotech’s latest IPO, raising $110M for neuroinflammatory drugs
The offering keeps new biotech stock offerings on their strongest pace in three years, accompanying an uptick in private company funding.
By Ben Fidler • April 4, 2024 -
Permission granted by Amylyx Pharmaceuticals
Amylyx to pull ALS drug from market in rare move
In the wake of a major trial failure, the company is withdrawing Relyvrio and cutting costs with a restructuring that involves laying off 70% of its employees.
By Jacob Bell • April 4, 2024 -
JaysonPhotography via Getty Images
Paragon’s hub-and-spoke biotech model yields another reverse merger
Oruka Therapeutics is the third startup from Paragon to go public since last year, and the second to do so by combining with another biotech.
By Jacob Bell • April 3, 2024 -
Kahan Shan via Getty Images
Emerging biotechDiagonal starts up with $128M to make better ‘activator’ antibody drugs
The startup claims to have a more efficient way to develop biologic drugs that treat disease by turning on cellular pathways, rather than blocking them.
By Gwendolyn Wu • April 3, 2024 -
Maximusnd via Getty Images
Roivant reveals positive immune drug data, share buyback plans
A Pfizer drug licensed to a Roivant subsidiary surpassed expectations in a type of uveitis, while a stock purchase plan will see Roivant buy out shares owned by Sumitomo Pharma.
By Delilah Alvarado • April 2, 2024 -
Michael M. Santiago via Getty Images
Acorda files for bankruptcy, reveals asset sale plan
Stalking horse bidder Merz Therapeutics could get rights to Acorda’s three marketed drugs if its $185 million proposal holds.
By Jacob Bell • April 2, 2024 -
Getty Images via Getty Images
A dementia-focused VC digs past amyloid for new kinds of brain drugs
The Dementia Discovery Fund set out to spark research into new approaches for diseases like Alzheimer’s, even as anti-amyloid therapies reach patients.
By Michael Gibney • April 2, 2024 -
Meletios Verras via Getty Images
Ginkgo, in search of more cell therapy tools, buys another startup
A deal for Modulus Therapeutics is the latest move by Ginkgo to accumulate technologies that can help other companies develop cellular medicines.
By Gwendolyn Wu • April 2, 2024 -
Courtesy of Vertex Pharmaceuticals
Vertex moves kidney disease drug into late-stage testing
The drug, inaxaplin, is an important pipeline prospect for Vertex, which is working to expand beyond the cystic fibrosis medicines that made its name.
By Delilah Alvarado • April 1, 2024 -
maciek905 via Getty Images
Emerging biotechBoundless Bio breaks IPO lull with $100M fundraise
The startup’s performance will test investors’ appetite for early-stage drugmakers, as Boundless has only advanced as far as Phase 1 clinical trials.
By Gwendolyn Wu • March 28, 2024 -
Permission granted by Gilead Sciences
Gilead bets on Xilio cancer drug as biotech restructures
Xilio will get just over $40 million from Gilead in return for a license to its experimental IL-12 immunotherapy. The biotech is also discontinuing other work and laying off staff.
By Ned Pagliarulo • March 28, 2024
